The Vanderbilt University

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Opioid Titration in the Hospice Setting: Barriers Assessment and Modification of the Model Order Sheet and Protocol

Completed

Conditions: Cancer Pain

Interventions: Other: interview, focus group and structured survey
Other: Individual patient interview, focus group and structured survey

First Posted Date: 2010-10-29

Last Posted Date: 2012-09-10

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 65

Registration Number: NCT01230515

Locations: 🇺🇸
Vanderbilt-Ingam Cancer Center, Nashville, Tennessee, United States

PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer

Phase 2

Terminated

Conditions: Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Stage IV Pancreatic Cancer

Interventions: Drug: STA-9090
Radiation: Radiologic imaging
Procedure: blood draw

First Posted Date: 2010-10-22

Last Posted Date: 2014-07-23

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 15

Registration Number: NCT01227018

Locations: 🇺🇸
The Jones Clinic, Memphis, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

PET/CT Evaluation of Treatment Response in Breast Cancer

Not Applicable

Terminated

Conditions: Breast Cancer

Interventions: Radiation: Radiopharmaceutical Administration [18F]-FDG

First Posted Date: 2010-10-18

Last Posted Date: 2017-07-02

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 50

Registration Number: NCT01222416

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Standard vs High-Dose Trivalent Inactivated Flu Vaccine in Adult Hematopoetic Stem Cell Transplant (HSCT) Recipients

Phase 1

Completed

Conditions: Adult Stem Cell Hematopoetic Transplant

Interventions: Biological: High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)
Biological: Standard Dose Trivalent Inactivated Flu Vaccine

First Posted Date: 2010-10-06

Last Posted Date: 2013-03-08

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 44

Registration Number: NCT01215734

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Clinical Trials Information Program, Nashville, Tennessee, United States

First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: VELCADE
Drug: DVT prophylaxis
Drug: Lenalidomide
Drug: Liposomal doxorubicin
Drug: Dexamethasone
Drug: Bisphosphonates

First Posted Date: 2010-10-06

Last Posted Date: 2018-05-15

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 36

Registration Number: NCT01215344

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
University of Tennessee Cancer Institute, Boston Baskin Cancer Group, Memphis, Tennessee, United States

Molecular Determinants Affecting Fluoro-L-thymidine (FLT) Positron Emission Tomography (PET) in Rectal Cancer

Phase 1

Completed

Conditions: Rectal Cancer

Interventions: Device: PET imaging with [18F]-FLT
Drug: [18F]-fluorodeoxythymidine

First Posted Date: 2010-09-23

Last Posted Date: 2017-02-23

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 5

Registration Number: NCT01207895

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment

Recruiting

Conditions: Melanoma

First Posted Date: 2010-09-21

Last Posted Date: 2024-02-07

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 3000

Registration Number: NCT01205815

Locations: 🇺🇸
Vanderbitl-Ingram Cancer Center, Nashville, Tennessee, United States

Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Hormone-sensitive Metastatic Breast Cancer

Interventions: Drug: OSI-906
Drug: Erlotinib
Drug: Letrozole
Drug: Goserelin

First Posted Date: 2010-09-20

Last Posted Date: 2012-09-11

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 11

Registration Number: NCT01205685

Locations: 🇺🇸
Vanderbilt-Ingram Oncology Cool Springs, Franklin, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Vanderbilt One Hundre Oaks, Nashville, Tennessee, United States

Internet-Based Clinical Information and Blood Sample Collection From Patients With Non-Small Cell Lung Cancer Who Never Smoked Cigarettes

Terminated

Conditions: Lung Cancer

Interventions: Other: internet-based protocol and physician referral

First Posted Date: 2010-06-10

Last Posted Date: 2017-04-25

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 88

Registration Number: NCT01141218

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Role of Biomarkers in Muscle Pain and Joint Pain in Patients With Solid Tumors Receiving Paclitaxel

Terminated

Conditions: Arthralgia
Pain
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Other: laboratory biomarker analysis
Other: questionnaire administration
Procedure: assessment of therapy complications

First Posted Date: 2010-03-31

Last Posted Date: 2013-04-04

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 5

Registration Number: NCT01096407

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy